Evidence map›Paper›PMID 31283756›Full record

Trial reportPloS one2019

T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization.

Werner Bystricky, Christoph Maier, Gary Gintant, Dennis Bergau, Kent Kamradt, Patrick Welsh, David Carter

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Werner BystrickyClinical Pharmacology, AbbVie Inc., North Chicago, Illinois, United States of America.ORCID 0000-0001-7764-729X
Christoph MaierClinical Pharmacology, AbbVie Inc., North Chicago, Illinois, United States of America.
Gary GintantIntegrated Sciences and Technology, AbbVie Inc., North Chicago, Illinois, United States of America.
Dennis BergauClinical Pharmacology, AbbVie Inc., North Chicago, Illinois, United States of America.ORCID 0000-0001-6484-1974
Kent KamradtClinical Pharmacology, AbbVie Inc., North Chicago, Illinois, United States of America.
Patrick WelshClinical Pharmacology, AbbVie Inc., North Chicago, Illinois, United States of America.ORCID 0000-0002-2459-4873
David CarterClinical Pharmacology, AbbVie Inc., North Chicago, Illinois, United States of America.ORCID 0000-0002-8102-7795
AbbVie (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe present a new family of ECG biomarkers for assessing drug effects on ventricular repolarization. We show that drugs blocking inward (depolarizing) ion currents cause a relative increase of the T vector velocity (TVV) and accelerate repolarization, while drugs blocking outward ion currents cause a relative decrease of the TVV and delay repolarization. The results suggest a link between the TVV and the instantaneous change of the cellular action potentials that may contribute to bridge the gap between the surface ECG and myocardial cellular processes.

methodsWe measure TVV as the time required to reach X% of the total Trajectory length of the T vector loop, denoted as TrX. Applied to data from two FDA funded studies (22+22 subjects, 5232+4208 ECGs) which target ECG effects of various ion-channel blocking drugs, the TrX effect profiles indicate increasingly delayed electrical activity over the entire repolarization process for drugs solely reducing outward potassium current (dofetilide, moxifloxacin). For drugs eliciting block of the inward sodium or calcium currents (mexiletine, lidocaine), the TrX effect profiles were consistent with accelerated electrical activity in the initial repolarization phase. For multichannel blocking drugs (ranolazine) or drug combinations blocking multiple ion currents (dofetilide + mexiletine, dofetilide + lidocaine), the overall TrX effect profiles indicate a superposition of the individual TrX effect profiles.

resultsThe parameter Tr40c differentiates pure potassium channel blocking drugs from multichannel blocking drugs with an area under the ROC curve (AUC) of 0.90, CI = [0.88 to 0.92]. This is significantly better than the performance of J-Tpeakc (0.81, CI = [0.78 to 0.84]) identified as the best parameter in the second FDA study. Combining the ten parameters Tr10c to Tr100c in a logistic regression model further improved the AUC to 0.94, CI = [0.92 to 0.96].

conclusionsTVV analysis substantially improves assessment of drug effects on cardiac repolarization, providing a plausible and improved mechanistic link between drug effects on ionic currents and overall ventricular repolarization reflected in the body surface ECG. TVV contributes to an enhanced appraisal of the proarrhythmic risk of drugs beyond QTc prolongation and J-Tpeakc.

Indexed as

Action PotentialsAdultDatabases, FactualDouble-Blind MethodElectrocardiographyFemaleHeartHumansLidocaineMaleMexiletinePhenethylaminesPotassium Channel BlockersRanolazineSodium Channel BlockersSulfonamidesdofetilideLidocaineMexiletinePhenethylaminesPotassium Channel BlockersRanolazineSodium Channel BlockersSulfonamidesVerapamil

Identifiers

PMID31283756
PMCPMC6613676
OpenAlexW2958004633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.